Narcolepsy: Epidemiology Forecast to 2027

Narcolepsy: Epidemiology Forecast to 2027

Summary

Narcolepsy is a chronic disorder that is mainly characterized by excessive daytime sleepiness and, in the majority of individuals, cataplexy-a sudden loss of muscle tone during wakefulness that is evoked by strong, usually positive, emotions. The onset of narcolepsy is during adolescence or early adulthood. While the exact cause of narcolepsy is unknown, the majority of cases have low levels of hypocretin, an important neurochemical that helps regulate wakefulness and rapid eye movement (REM) sleep.

Patients with narcolepsy can also experience disturbed nighttime sleep, sleep paralysis, hypnagogic hallucinations, or hypnopompic hallucinations. Narcolepsy is not a rare disease, but is frequently misdiagnosed or undiagnosed.

In the 7MM for 2017, the US accounted for 40.75% of the total prevalent cases of narcolepsy, 5EU combined made up 44.33% of the total prevalent cases of narcolepsy, and Japan accounted for 14.91% of the total prevalent cases of narcolepsy. In 2017, the 7MM had 378,279 total prevalent cases of narcolepsy. This is expected to increase to 393,534 cases by 2027, at an annual growth rate (AGR) of 0.40%. With the advent of objective testing, there could be an increase in the timely diagnosis, diagnosis rate, and treatment of patients with narcolepsy.

Within the report "Narcolepsy: Epidemiology Forecast to 2027", epidemiological forecast is supported by country-specific data, which provide detailed insights into the epidemiology of the disease in each market. Epidemiologists used nationally representative, country-specific studies published in peer-reviewed journals of national healthcare databases and registries to forecast the total and diagnosed prevalent cases of narcolepsy in the 7MM. In addition, epidemiologists used sources that provided uniform diagnostic criteria as defined by the International Classification of Sleep Disorders (ICSD-3).

This report provides an overview of the risk factors and the global and historical trends for narcolepsy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiology forecast of the total prevalent and the diagnosed prevalent cases of narcolepsy cases in these markets from 2017-2027. The prevalent cases are further segmented by sex and age (15-39 years, 40-59 years, 60-79 years, and 80 years and older) and by type (NT1 and NT2).

Scope

• The Narcolepsy Epidemiology Forecast Report provides an overview of the risk factors and global trends of narcolepsy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).


• This report also includes 10-year epidemiology forecast of the total prevalent cases (both diagnosed and undiagnosed) and diagnosed prevalent cases of narcolepsy in these markets from 2017-2027. Both types of prevalent cases are further segmented by sex and age (15-39 years, 40-59 years, 60-79 years, and 80 years and older) and by type (NT1 and NT2).


• The narcolepsy epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.


• The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Narcolepsy Epidemiology Forecast report will allow you to:

• Develop business strategies by understanding the trends shaping and driving the global narcolepsy market.


• Quantify patient populations in the global narcolepsy market to improve product design, pricing, and launch plans.


• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for narcolepsy therapeutics in each of the markets covered.


• Understand magnitude of narcolepsy population by type 1 and type 2 forms.